BusinessFibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)By Nasdaq OMXOct 18, 2017, 11:01 AM UTC
BusinessPositive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseaseBy Nasdaq OMXMar 30, 2017, 11:02 AM UTC
BusinessPositive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseaseBy Nasdaq OMXMar 30, 2017, 11:02 AM UTC
BusinessFibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in ChinaBy Nasdaq OMXJan 30, 2017, 12:00 PM UTC
BusinessFibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney DiseaseBy Nasdaq OMXFeb 16, 2016, 12:20 PM UTC
